Breast Cancer Hr-positive
📧 Sign up to get email alerts when something new happens for Breast Cancer Hr-positive.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers [Phase 1]
A Phase I trial evaluating [177Lu]Lu-NNS309, a radiopharmaceutical, in multiple advanced cancers including pancreatic ductal adenocarcinoma,…
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies [Phase 1, Phase 2]
Clinical trial update for BT8009-100 in nectin-4 expressing advanced malignancies (Phase 1/2) with status ACTIVE_NOT_RECRUITING.
-
CLINICAL_TRIALS trial_result · 2024-09-27Clinical Trial Update: A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors [Phase 1]
Phase 1 study of LY3300054, an anti-PD-L1 antibody, given alone or in combination in adults with advanced refractory solid tumors, including…
-
FDA approval · 2021-10-18FDA Approved: EVEROLIMUS — Original Application (Par Health USA, LLC)
FDA approved Par Health USA, LLC's Original Application for EVEROLIMUS (a generic version of everolimus). The approval enables the generic p…
-
FDA approval · 2020-02-13FDA Approved: AFINITOR — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Afinitor (everolimus) from Novartis Pharmaceuticals Corporation.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.